Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 766093 | ISIN: US7665596034 | Ticker-Symbol: RI2A
Stuttgart
28.03.24
08:02 Uhr
1,337 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
RIGEL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
RIGEL PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,3101,38509:26
1,3101,38509:26

Aktuelle News zur RIGEL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.03.Rigel Pharmaceuticals names new Chief Medical Officer1
12.03.Rigel Pharma Names Rojkjaer EVP, Chief Medical Officer210WASHINGTON (dpa-AFX) - Tuesday, Rigel Pharmaceuticals, Inc. (RIGL) appointed Lisa Rojkjaer, as executive vice president and chief medical officer. Rojkjaer, a board-certified hematologist with...
► Artikel lesen
12.03.Rigel Pharmaceuticals, Inc.: Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer102SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief...
► Artikel lesen
12.03.Aurous to merge with Rigel for NASDAQ listing2
07.03.Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript3
06.03.Rigel Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary3
05.03.Rigel Pharmaceuticals GAAP EPS of $0.00 beats by $0.02, revenue of $35.8M beats by $2.39M2
05.03.Rigel Pharmaceuticals Inc. Q4 Earnings Summary583WASHINGTON (dpa-AFX) - Below are the earnings highlights for Rigel Pharmaceuticals Inc. (RIGL):Earnings: $0.74 million in Q4 vs. $1.40 million in the same period last year. EPS: $0.00 in Q4...
► Artikel lesen
05.03.Rigel Pharmaceuticals: Q4 Earnings Insights2
05.03.RIGEL PHARMACEUTICALS INC - 8-K, Current Report3
05.03.RIGEL PHARMACEUTICALS INC - 10-K, Annual Report2
05.03.Rigel Pharmaceuticals, Inc.: Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update62Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE® net product sales of $25.7 million and REZLIDHIA® net product sales of $3.9 million Expanded product portfolio with acquisition...
► Artikel lesen
04.03.Earnings Outlook For Rigel Pharmaceuticals1
23.02.After Roche's exit, Blueprint passes Gavreto on to Rigel26
22.02.After Roche breakup, Blueprint Medicines finds Gavreto a new home at Rigel35
22.02.Rigel Pharmaceuticals rises after acquiring US rights to lung cancer drug3
22.02.Rigel Pharmaceuticals adds GAVRETO to its portfolio4
22.02.RIGEL PHARMACEUTICALS INC - 8-K, Current Report1
22.02.Rigel Pharmaceuticals, Inc.: Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO187GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Acquisition of...
► Artikel lesen
19.02.Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?4
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1